Routine board appointment with no trading signal. Monitor for any future pipeline updates or financial disclosures, but this filing alone does not warrant a position change.
VTGN drugs
VTGN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 31 $0.2410entry
- T+1 · 4mo ago +1.66%α +0.24% · $0.2450
- T+5 · 3mo ago +19.34%α +15.82% · $0.2876
- T+20 · 3mo ago +4.94%α +1.95% · $0.2529
- T+60 · 22d ago −27.88%α −30.34% · $0.1738
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vistagen Therapeutics appointed Douglas J. Williamson, M.D. to its Board of Directors effective July 29, 2026. Dr. Williamson received stock options to purchase 40,826 shares at $0.2433 per share, vesting over three years. This is a routine board appointment with no material financial or operational impact.
Key Facts
- Douglas J. Williamson, M.D. appointed to the Board of Directors on July 29, 2026.
- Received options to purchase 40,826 shares of common stock at an exercise price of $0.2433 per share (closing price on appointment date).
- Options vest in equal annual installments over three years, fully vested on the three-year anniversary.
- Dr. Williamson also entitled to annual cash compensation and equity awards under the Director Compensation Plan.
- Company entered into a standard Indemnification Agreement with Dr. Williamson.
Financial Impact
No material financial impact. The option grant is standard director compensation with a strike price at market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-051251 |
| Document: vtgn-20260729.htm | 0001628280-26-051251 |
| Document: vtgn20260731ex991.htm | 0001628280-26-051251 |
| Document: 0001628280-26-051251-index-headers.html | 0001628280-26-051251 |
| Document: 0001628280-26-051251-index.html | 0001628280-26-051251 |
| Document: 0001628280-26-051251.txt | 0001628280-26-051251 |
Track record
21 reports on VTGN
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers